Survodutide Shows No Added Heart Risk
A 5,530-person trial found the investigational obesity drug did not raise major cardiovascular events compared with placebo.
Updated on Nov. 9, 2026 in Weight Loss
Survodutide, an investigational glucagon/GLP-1 receptor dual agonist, did not increase major adverse cardiovascular events versus placebo in the SYNCHRONIZE-CVOT trial. The drug is not approved for any use.
Why it matters
Cardiovascular safety is a central requirement for new weight-loss drugs, particularly for adults with existing heart or kidney disease. Boehringer Ingelheim is preparing regulatory submissions for survodutide in obesity based on the full SYNCHRONIZE program.
The trial enrolled 5,530 adults with obesity or overweight and established cardiovascular or kidney disease or related risk factors, with a 5-point MACE hazard ratio of 0.89 versus placebo (95% CI, 0.67-1.18). Gastrointestinal discontinuation reached 19.3% to 20.8% on survodutide versus 1.9% on placebo, and long-term outcomes beyond the trial window remain unknown.
The players
Boehringer Ingelheim
A privately held German pharmaceutical company that develops drugs across human and animal health and is sponsoring survodutide's development.
American Heart Association
A U.S.-based nonprofit focused on cardiovascular health whose Scientific Sessions 2026 served as the venue where the results were presented.
The details
Participants received once-weekly survodutide at 3.6 mg or 6.0 mg, or placebo, and the primary end point was time to first 5-point MACE, including cardiovascular death, nonfatal heart attack or stroke, coronary revascularization, or heart failure events. Over 72 weeks, body weight fell by up to 13.7% versus 2.0% on placebo, and systolic blood pressure dropped by up to 6.68 mm Hg versus 1.76 mm Hg.
Timeline
72 weeks: blood pressure, waist and weight reductions measured in the trial.
November 9, 2026: SYNCHRONIZE-CVOT results presented and published.
Health Landscape
Regulators have required cardiovascular outcomes trials for new glucose-lowering drugs since the FDA's 2008 diabetes guidance. Survodutide's trial applies that same safety standard to an obesity drug, which is increasingly the focus of cardiometabolic research.
If approved, survodutide would add a new option for adults with obesity who also have heart or kidney disease, a group that often faces limited weight-loss choices. Gastrointestinal side effects led to treatment discontinuation for roughly one in five participants on the higher doses, which patients would need to weigh with their clinicians.
The takeaway
Cardiovascular safety data is becoming a standard requirement for obesity drugs, not just diabetes treatments. Readers considering any emerging weight-loss medication should discuss gastrointestinal tolerability and heart health with their doctor before deciding.
What happens next
Boehringer Ingelheim is preparing regulatory submissions for survodutide in obesity, though no submission dates have been specified.
Further reading
Explore more on Weight Loss to see how emerging obesity drugs are being evaluated.
